Age-Related Macular Degeneration Market Report 2026

The age-related macular degeneration market size has grown strongly in recent years. It will grow from $10.67 billion in 2025 to $11.46 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population globally, rising prevalence of amd, limited treatment options in early years, growing awareness of eye health, increasing hospital and ophthalmology clinic infrastructure.

The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $15.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to development of next-generation anti-vegf drugs, growing investment in ophthalmology research, expansion of specialty pharmacies and online pharmacy channels, increasing use of combination therapies, rising adoption of personalized treatment approaches. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of nutritional supplements and low vision aids, growth in photodynamic and laser therapy procedures, expansion of intravitreal and intravenous administration routes, increasing awareness and regular eye screening programs.

The rising prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the age-related macular degeneration (AMD) market in the coming years. Age-related macular degeneration (AMD) is a progressive eye disorder affecting the macula, the small area of the retina responsible for central vision. AMD treatments assist patients with retinal disorders by reducing the severity and progression of the disease. For instance, in February 2023, according to reports shared by Optimaxa, a UK-based laser eye treatment specialist, AMD affected 196 million individuals globally and is projected to reach 288 million by 2040, representing 8.7 percent of the world’s population. Therefore, the rising prevalence of age-related macular degeneration (AMD) is contributing to the growth of the AMD market.

Major companies in the age-related macular degeneration (AMD) market are focusing on advancing innovative technologies, such as recombinant antigen-binding fragments. Recombinant antigen-binding fragments (Fab) are engineered proteins derived from antibodies that specifically target antigens and are commonly used in therapeutic applications to inhibit disease-related pathways. For instance, in December 2023, Enzene Biosciences, an India-based biotechnology company, launched ranibizumab, a recombinant monoclonal antibody fragment (Fab) engineered to inhibit vascular endothelial growth factor (VEGF), a key protein involved in the formation of abnormal blood vessels in conditions such as AMD and diabetic macular edema (DME). By blocking VEGF, ranibizumab reduces the leakage and growth of these blood vessels, helping preserve vision in patients with retinal disorders. Delivered via intravitreal injection, ranibizumab has become widely accepted in clinical practice for its effectiveness in treating various retinal diseases, significantly enhancing the treatment landscape for affected patients.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to strengthen its presence in the ophthalmology market and accelerate the development of novel ophthalmic treatments. IVERIC Bio Inc. is a US-based biotechnology company focused on developing drugs and therapies for age-related macular degeneration.

Major companies operating in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Outlook Therapeutics Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

North America was the largest region in the global age-related macular degeneration market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the age-related macular degeneration market by increasing the cost of imported anti-vegf drugs, medical devices, and laser therapy equipment. Segments such as wet amd therapies and photodynamic devices are most affected, with north america, europe, and asia-pacific regions facing higher import costs. This has led to increased treatment expenses and supply chain delays. On the positive side, tariffs have encouraged local manufacturing, development of biosimilars, and investment in domestic production capabilities.

The age-related macular degeneration market research report is one of a series of new reports that provides age-related macular degeneration market statistics, including age-related macular degeneration industry global market size, regional shares, competitors with a age-related macular degeneration market share, detailed age-related macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the age-related macular degeneration industry. This age-related macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Age-related macular degeneration (AMD) is a progressive eye condition in which the macula, located at the center of the retina, gradually deteriorates over time, causing a decline in central vision. This condition is associated with aging. Treatment options for age-related macular degeneration include regular eye examinations, lifestyle modifications, and specific nutritional supplements.

The main types of age-related macular degeneration are wet AMD and dry AMD. Wet age-related macular degeneration is a progressive eye disease in which abnormal blood vessels begin to grow beneath the macula, the central part of the retina responsible for sharp, central vision. It is treated with various drugs such as Eylea, Lucentis, Avastin, and others. These medications are administered intravenously or intravitreally and are distributed through hospital pharmacies, specialty pharmacies, and online pharmacies.

The age-related macular degeneration market consists of sales of anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), low-vision aids, and telescopic lenses. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.